Table 1.
Clinical characteristics of patients with PPGL (n = 30).
| Characteristics | |
|---|---|
| Age (years) | 40.4 ± 14.5 |
| Female, n (%) | 17 (56.7%) |
| Body mass index (kg/m2) | 21.54 ± 3.42 |
| Waist circumference (cm) | 80.88 ± 10.52 |
| PCC unilateral, n (%) | 21(91.3%) |
| PCC bilateral, n (%) | 2 (8.7%) |
| Extra-adrenal (PGL), n (%) | 7 (23.3%) |
| Tumor diameter (cm) | 4.0 (3.4–5.5) |
| Asymptomatic, n (%) | 5 (16.7%) |
| Symptomatic, n (%) | 25 (83.3%) |
| Headache, n (%) | 15 (50%) |
| Palpitations, n (%) | 14 (46.7%) |
| Persistent hypertension, n (%) | 16 (53.3%) |
| Beta-blockers, n (%) | 18 (60%) |
| Alpha-blockers, n (%) | 29 (96.7%) |
| Hyperglycemia, n (%) | 16 (53.3%) |
| Dyslipidemia, n (%) | 9 (30%) |
| Fasting plasma glucose (mmol/L) | 6.1 (4.9–6.6) |
| Fasting plasma total GLP-1 (pmol/L) | 27.8 ± 14.7 |
| DPP-IV inhibitors or GLP-1 agonists, n (%) | 0 |
| Insulin therapy, n (%) | 7 (23.3%) |
| Triglyceride (mmol/L) | 1.31 ± 0.67 |
| LDL-C (mmol/L) | 3.17 ± 0.79 |
| HDL-C (mmol/L) | 1.37 ± 0.32 |
| Serum creatinine (umol/L) | 66.5 (56.0–74.3) |
| Plasma metanephrine (nmol/L) | 1.09 (0.21–3.66) |
| Plasma normetanephrine (nmol/L) | 9.11 (4.23–20.56) |
Data are expressed as mean ± SD or median (internal quartile range (IQR)). PPGL: pheochromocytoma and paraganglioma; PCC: pheochromocytoma; PGL, paraganglioma; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; GLP-1, glucagon-likepeptide-1.